Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01794741 · ClinicalTrials.gov registry record · Phase 3
3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
A Phase 3 study of Allergic Rhinitis, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 405
- Enrollment target
- 20
- Study locations
NCT01794741 is a Phase 3 study of Allergic Rhinitis that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 405 participants, above the 88-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (360% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT01794741, a Phase 3 study of Allergic Rhinitis, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 405 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis
Conditions Studied
Interventions
- DRUG Dymista Nasal Spray
- DRUG Fluticasone propionate nasal spray
Study Locations (20)
California
- West Coast Clinical Trials - Costa Mesa
- Allergy & Asthma Care Center of So. Cal - Long Beach
- Southern California Research - Mission Viejo
- Allergy Associates Medical Group Inc - San Diego
- Allergy & Asthma Associates of Santa Clara Valley Research Cntr - San Jose
Colorado
- Storms Clinical Research Institute - Colorado Springs
- Colorado Allergy and Asthma Centers, PC - Denver
- Asthma and Allergy Associates, PC - Pueblo
Missouri
- The Clinical Research Center - St Louis
- Clinical Research of the Ozarks,Inc - Warrensburg
Alabama
- Clinical Research Center of Alabama,LLC - Birmingham
Alaska
- Little Rock Allergy and Asthma Clinical research Center - Little Rock
Florida
- Allergy and Asthma Care of Florida - Ocala
Georgia
- Atlanta Allergy and Asthma Clinic - Stockbridge
Idaho
- Idaho Allergy - Eagle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 405 participants |
| Start Date | 2013-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01794741
The ClinicalTrials.gov registry entry for NCT01794741 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 405 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 88-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (360% higher). The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Dymista Nasal Spray is the first listed.
NCT01794741 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Colorado, Missouri.
Frequently Asked Questions
What is clinical trial NCT01794741 about?
NCT01794741 is a clinical study titled "3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis". This is a 3 month safety study of Dymista Nasal spray in children aged 4 to 11 years with allergic rhinitis
What is the current status of trial NCT01794741?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 405 participants. The study started on 2013-02.
What conditions does trial NCT01794741 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT01794741?
The interventions under investigation include: Dymista Nasal Spray (DRUG), Fluticasone propionate nasal spray (DRUG).
Who is sponsoring clinical trial NCT01794741?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01794741 being conducted?
This trial has 20 study locations across Alabama, Alaska, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
-
Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies
COMPLETED · Phase 3
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.